Clinical Trial Update: Positron Emission Tomagraphy (PET) Study Following a Single Oral Dose of OPC-34712 [Phase 1]

View source ↗

Summary

This Phase 1 PET imaging study evaluated brain pharmacokinetics and occupancy after a single oral dose of OPC-34712 in individuals with schizophrenia, and the t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• OPC-34712

Snippet

Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. | Conditions: Schizophrenia | Phase 1 | Status: COMPLETED